Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial

Miklos Pless(Ontario Institute for Cancer Research), Solange Peters(University Hospital of Lausanne), Rolf A. Stahel(International Breast Cancer Study Group), Alexandros Xyrafas(Swiss Group For Clinical Cancer Research), Adrian F. Ochsenbein(University of Bern), Martin Früh(University of Bern), Sandra Thierstein(Swiss Group For Clinical Cancer Research), Richard Cathomas(Kantonsspital Graubünden), Roger Stupp(Northwestern University), Milorad Bijelović(Institute for Pulmonary Diseases of Vojvodina), Alfred Zippelius(University of Basel), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Walter Weder(Krankenhaus Bethanien), Christoph Mamot(Kantonsspital Aarau), Urs R. Meier(Kantonsspital Winterthur), Hans-Beat Ris(Centre Hospitalier Universitaire Vaudois), René-Olivier Mirimanoff(Clinique de La Source), Arnaud Roth(Hôpital Beau-Séjour), Daniel Betticher, Marie-Aline Gérard(Swiss Group For Clinical Cancer Research), Daniel Rauch(Washington University in St. Louis)
The Lancet
August 11, 2015
10.1016/s0140-6736(15)60294-x
Cited by 392

Related Papers

<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
|Annals of Oncology|2018|2.9k
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
|JAMA|2017|2.5k
Alectinib versus Crizotinib in Untreated <i>ALK</i>-Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2017|2.4k